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ABSTRACT
Background. Cathepsin E (CTSE), an aspartic proteinase,
is differentially expressed in the metaplasia–dysplasia–
neoplasia sequence of gastric and colon cancer. We eval-
uated CTSE in Barrett’s esophagus (BE) and cancer
because increased CTSE levels are linked to improved
survival in several cancers, and other cathepsins are up-
regulated in BE and esophageal adenocarcinoma (EAC).
Methods. A total of 273 pretreatment tissues from 199
patients were analyzed [31 normal squamous esophagus (NE),
29 BE intestinal metaplasia, 31 BE with dysplasia (BE/D), 108
EAC]. CTSE relative mRNA expression was measured by
real-time polymerase chain reaction, and protein expression
was measured by immunohistochemistry. CTSE serum levels
were determined by enzyme-linked immunosorbent assay.
Results. Median CTSE mRNA expression levels were
C1,000-fold higher in BE/intestinal metaplasia and BE/D
compared to NE. CTSE levels were significantly lower in
EAC compared to BE/intestinal metaplasia and BE/D, but
significantly higher than NE levels. A similar expression
pattern was present in immunohistochemistry, with absent
staining in NE, intense staining in intestinal metaplasia and
dysplasia, and less intense EAC staining. CTSE serum
analysis did not discriminate patient groups. In a uni- and
multivariable Cox proportional hazards model, CTSE
expression was not significantly associated with survival in
patients with EAC, although CTSE expression above the
25th percentile was associated with a 41 % relative risk
reduction for death (hazard ratio 0.59, 95 % confidence
interval 0.27–1.26, p = 0.17).
Conclusions. CTSE mRNA expression is up-regulated
more than any known gene in Barrett intestinal metaplasia
and dysplasia tissues. Protein expression is similarly highly
intense in intestinal metaplasia and dysplasia tissues.
Barrett’s esophagus (BE) is the condition in which the
normal distal squamous lining of the esophagus is replaced
by specialized metaplastic columnar epithelium.1 BE is the
strongest recognized risk factor for esophageal adenocar-
cinoma (EAC), a highly malignant cancer with an
unparalleled 6-fold increase in incidence over the past three
decades.2 Less than 5 % of patients presenting with EAC
have a previous diagnosis of BE because they have not
undergone endoscopy, but even for patients under surveil-
lance, there are significant problems, including sampling
error and difficulties with the histopathologic interpretation
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of degree of dysplasia, and EAC may develop between
endoscopies.3–5
These problems have stimulated the search for clinically
relevant biological markers, but so far, no biomarkers have
proven sufficient for routine clinical practice.6,7 Because of
the problems with endoscopic diagnosis and surveillance, it
is worth exploring non endoscopic, cheaper, and less-
invasive diagnostic and monitoring options, such as blood,
saliva, and brush cytology tests.
Cathepsin E (CTSE) is an intracellular aspartic protease
that is normally expressed in a wide range of immune cells
but also is present in osteoclasts and gastric epithelial cells;
secreted forms have been described.8–10 A differential
expression pattern has been demonstrated for CTSE in
normal, metaplastic, dysplastic, and neoplastic gastric
epithelium as well as in the intestinal dysplasia–neoplasia
sequence in APCmin/? mice.11–15 Furthermore, CTSE has
also been suggested as both a diagnostic and a prognostic
biomarker for some cancers.16
Other members of the cathepsin family (cathepsin B, C,
D, K, and S) have been found to be up-regulated in BE and
EAC, but analysis of CTSE in BE and EAC has not been
reported.17–20
This study aimed to evaluate the potential prognostic value
of CTSE to predict progression to more advanced disease in
patients with Barrett metaplasia–dysplasia–adenocarcinoma
spectrum, and to predict survival for patients with EAC.
MATERIALS AND METHODS
Study Design, Study Population, and Specimen
Collection
A diagnostic case control analysis was performed to
examine the associations among the following: (1) CTSE
tissue mRNA expression and normal squamous esophagus
(NE), BE, BE with dysplasia (BE/D) and EAC; (2) CTSE
serum protein levels and NE, BE, BE/D and EAC; and (3)
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FIG. 1 CTSE mRNA expression analysis (a). CTSE is increased in
BE and BE/D in comparison to NE. CTSE mRNA expression of
CTSE in EAC is significantly lower than BE and dysplastic BE, but is
significantly higher compared to NE. Immunohistochemical staining
for CTSE (d–f). Marked, intense staining in BE and EAC with
decreased staining intensity and shift in staining pattern with
neoplastic progression of Barrett epithelium. Quantification of these
findings could be statistically confirmed (b, c)
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the association between CTSE and overall EAC patient
survival (Supplementary Fig. 1).
The NE, BE, and BE/D tissues as well as blood samples
were collected at endoscopies performed at St. Vincent’s
Hospital, Sydney, from patients prospectively enrolled onto
a research collaboration entitled PROBE-NET (Progression
of Barrett’s Esophagus to Esophageal Adenocarcinoma
Network). The EAC specimens were obtained either from
patients at St. Vincent’s Hospital or from patients who had
been enrolled onto the population-based case-control
Australian Cancer Study.21 All tissues were fixed in for-
malin and embedded in paraffin. The pathology diagnosis
was established by pathologists at the respective host
institutions. Before mRNA extraction, a section of each
tissue sample was also sent for hematoxylin and eosin
staining and reviewed to confirm the pathology in the
research specimen. BE was defined as intestinal metaplasia
with the presence of goblet cells. Patient serum samples
were collected at study recruitment, centrifuged at
14,0009 g, and then stored at -80 C until further use.
For the analysis of CTSE as a prognostic marker for EAC
survival, we used tissue samples from an independent cohort
of 75 patients with early stage EAC (I–IIB) from the Aus-
tralian Cancer Study.21 All subjects had undergone treatment
with potentially curative surgery alone and received no
chemo- or radiotherapy. Patients who died within 30 days of
surgery or who had cancer-involved operative resection
margins (R1/R2 resection) were excluded.
Institutional review board approval for this study was
obtained at all collaborating institutions, and all patients
provided written informed consent.
RNA Isolation
From each paraffin-embedded tissue block, two 7 lm
sections were cut and used for RNA extraction using the
Qiagen FFPE RNeasy Kit (Cat. #74404; Qiagen, Valencia,
CA) following the manufacturer’s protocol. RNA yield and
quality was measured using a Biospec Nano spectrophotom-
eter (Shimadzu Scientific Instruments, Sydney, Australia).
Multiplexed Tandem Polymerase Chain Reaction
Multiplexed tandem polymerase chain reaction (MT-PCR)
was used to quantitate the mRNA expression level of CTSE
and a reference gene, NONO (non-POU domain containing,
octamer-binding (NONO), transcript variant 2; NM_007363),
using the Rotor-Gene 6000 real-time quantitative PCR system
(Corbett Life Sciences/Qiagen, Sydney, Australia), as
described previously.22,23 Primers were designed with the
help of Primer 3 software modified by AusDiagnostics Pty.
Ltd. (AusDiagnostics, Alexandria, New South Wales, Aus-
tralia), leading to a CTSE ‘‘inner’’ amplicon of 73 bp and an
‘‘outer’’ amplicon of 120 bp. Outer primer sequences for
CTSE were 50-CTCAATGGACCAGAGTGCCAAG-30 (for-
ward) and 50-GAGGAGCCAGTGTCGAAGATG-30 (reverse).
Inner primer sequences were 50-GAGTGCCAAGGAACCC
CTCATC-30 (forward) and 50-TGGTGGGGAGCCAATGG
AGATA-30 (reverse). All primer pairs spanned an intron–
exon boundary, and all samples were run in duplicate. The
correct size and integrity of the products was verified on a
Bioanalyzer DNA separation chip (Agilent Technologies,
Forest Hill, Victoria, Australia).
CTSE Enzyme-Linked Immunosorbent Assay
A CTSE enzyme-linked immunosorbent assay (ELISA)
kit (Biomatik Corp, Cambridge, Ontario, Canada) was used
to measure CTSE protein levels in serum. Briefly, after
reconstitution of all reagents, serum samples were incu-
bated on precoated plates at 37 C and 70 % humidity for
2 h. After addition of the primary antibody and incubation
for another hour at 37 C, plates were washed three times
with wash buffer. Addition of the secondary antibody was
followed by a further incubation for 30 min at 37 C, and
plates were then washed another five times before the
addition of the reaction substrate. For antibody binding
detection, the supplier’s detection reagent was added for
15 min and the reaction halted by addition of the provided
stopping solution. Plate readouts occurred in a 96-well
multiplate reader (Multiskan Microplate Reader; Thermo
Labsystems/Thermo Scientific, Waltham, MA) at an
absorbance of 450 nm. All samples were assayed in trip-
licate and run without dilution. All plate readings had an
intra-assay coefficient of variation\15 %.
Immunohistochemistry
Tissue specimens were processed in a standard fashion
with regular formalin fixation and paraffin embedding.
CTSE was identified in 5 lm tissue sections using a rabbit
polyclonal anti-CTSE antibody (Cat. #ab36996; Abcam,
Waterloo, NSW, Australia) in a standard alkaline phos-
phatase anti-alkaline phosphatase technique, as described
previously.24
Immunohistochemistry Scoring
The sections were scored using a four-step scale: (0) no
staining or equal to background, (1) weak diffuse cyto-
plasmic staining, (2) moderate cytoplasmic staining in at
least 10 % of cells, and (3) strong immunostaining in a
majority of cells.25 Immunohistochemistry sections were
scored by two experienced investigators who were blinded
to clinical information. In cases of disagreement, consensus
was reached after reanalysis on a multiheaded microscope.
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Statistical Analysis
The mRNA raw expression values were obtained on the
Rotor-Gene MT-PCR system, and then relative expression
values were calculated as the ratio of the mRNA level of
CTSE to the control gene NONO, with the expression of
NONO set to a fixed level (1000). Where necessary, log2
transformation of relative expression values and/or serum
values was performed to achieve normal distribution. Dif-
ferences between two groups were measured by Student’s
t test or the Wilcoxon rank-sum test. One-way analysis of
variance was used to compare differential gene and protein
expression between patient groups. The Kaplan–Meier
method was used for survival estimates, and differences in
survival were analyzed using the log-rank test. Cox propor-
tional hazards models were used for uni- and multivariable
analysis. All p values of B0.05 were regarded as statistically
significant. All analyses were performed by the SAS Statis-
tical Package, version 9.2 (SAS Institute, Cary, NC). Prism
(GraphPad Prism version 6.0c for Mac OS X; GraphPad
Software, San Diego, CA) was used for graphs.
RESULTS
Patients and Tissues
As shown in Table 1, a total of 273 tissue specimens from
199 patients were included. Ninety-one patients were studied
to evaluate CTSE as a marker for the progression of BE to
EAC, 33 patients provided serum samples to evaluate CTSE
as a biomarker in blood, and 75 early-stage EAC patients were
included in the evaluation of CTSE as a prognostic biomarker.
TABLE 1 Clinical and pathologic characteristics of included patients




Prognostic biomarker in EAC
(n = 75)
n % n % n % n %
Sex
Male 164 82.4 67 73.6 29 87.9 68 90.7
Female 35 18.6 24 26.4 4 12.1 7 9.3
Age, year, median (IQR) 63 (55–71) 62 (53–69) 63 (54–70) 67 (59–74)
Diagnosis
Healthy controls/normal squamous 31 15.6 22 24.2 9 27.3 – –
BE intestinal metaplasia 29 14.6 21 23.1 8 24.2 – –
BE with dysplasia 31 15.6 22 24.2 9 27.3 – –
Esophageal adenocarcinoma 108 54.2 26 28.5 7 21.2 75 100
TNM (AJCC, 7th edition)
Tis 2 1.9 2 7.7 – – – –
T1–2 88 81.5 8 30.7 5 71.4 75 100
T3–4 8 7.4 6 23.1 2 28.6 – –
N1–3 34 31.5 7 26.9 3 42.9 24 32.0
M? 3 2.8 3 11.5 – – – –
Unknown T, N or M 10a 9.3 10a 38.5 – – – –
Tumor stage (AJCC, 7th edition)
0 (Tis) 2 1.9 2 7.7 – – – –
IA–B 33 30.6 2 7.7 3 42.9 28 37.3
IIA 26 24.1 2 7.7 1 14.3 23 30.7
IIB 29 26.9 4 15.4 1 14.3 24 32.0
IIIA–C 7 6.5 5 19.2 2 28.6 – –
IV 3 2.8 3 11.5 – – – –
Unknown stage 8a 7.4 8a 30.8 – – – –
Survival, d, median (range) 1,182 (630–1,685) 1,305 (195–1,780) 1,277 (766–1,342) 1,161 (724–1,663)
Totals may not equal 100 % due to rounding
BE Barrett’s esophagus, EAC esophageal adenocarcinoma, IQR interquartile range, TNM tumor, node, metastasis classification system, AJCC
American Joint Committee on Cancer
a Two patients included had no clinical data on T and N status but were found to be M? at assessment. Regardless of this, primary tissue
samples were used for analysis in the respective study. These patients were excluded from survival analysis
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Each part of the study included an independent cohort of
patients, thus allowing for intrastudy validation of CTSE as a
marker for the respective pathologies. Despite chart review,
the correct tumor stage could not be assessed in 8 patients
(7.4 %) as a result of incomplete clinical data.
Expression Analysis As shown in Fig. 1a, median CTSE
mRNA relative expression was more than 1,000-fold
higher in BE compared to NE (18.41 vs. 23,221;
p\ 0.001). Median CTSE mRNA expression in EAC
was lower than in BE and dysplastic BE (p\ 0.001) but
higher than in NE (875.14 vs. 18.41; p = 0.0024).
Immunohistochemistry All BE specimens and all EAC
specimens stained strongly for CTSE, with high specificity
to the glandular structures and almost absent staining of the
stromal fraction of the esophageal specimens. Figure 1d–f
provides representative immunostaining patterns of the
respective histopathology tissue types.
CTSE staining was completely absent within the squa-
mous epithelium, whereas in BE/D median staining scores
were 2.25 (p\0.001, Fig. 1b). Staining intensities in EAC
were similar to BE (median staining score 2.0), but the
location shifted more apically and the staining pattern
showed more granular features in EAC. Staining in EAC
was significantly lower than in BE/D (2.0 vs. 2.25;
p = 0.016, Fig. 1b).
CTSE immunostaining was also assessed in cardiac and
gastric fundus mucosa because CTSE is known to be present
in gastric glands.13 CTSE staining was significantly higher
in both proximal gastric mucosae compared to BE (2.0 vs.
2.5 and 3.0; p = 0.0067 and\0.001, respectively; Fig. 1c).
CTSE Serum ELISA As shown in Fig. 2, there were no
significant differences between patient groups.
Analysis of CTSE as a Prognostic Biomarker in Early-
Stage EAC
Patient Survival Overall median survival of the patients in
the independent EAC cohort was 3.2 years (38.7 months),
and overall 5-year survival was 66 %.
T1a and T1b patients showed a significantly increased sur-
vival (58.7 and 46.0 months, respectively) compared to T2
patients (25.2 months;p\0.001). Stage I (IA?B) patients had
a median survival of 41.2 months (3.4 years), whereas stage II
(IIA?IIB) survived 31.4 months (2.61 years, p = 0.0027).
CTSE mRNA Expression and Tumor Stage
No significant difference was found in CTSE expression
levels between T stages, American Joint Committee on
Cancer (AJCC) stage I versus II cancers, lymph node
negative versus positive disease, or male versus female sex
(data not shown).
CTSE EAC Tissue mRNA Expression and Survival For
survival analysis, CTSE expression values were
dichotomized at the 25th percentile, median, and 75th
percentile to determine the influence of CTSE expression
on overall patient survival. Kaplan–Meier survival curves
showed that patients with a CTSE expression above the
25th percentile had a non-significant trend toward
improved overall survival (log-rank p = 0.14, Fig. 3). In
uni- and multivariable analysis, elevated CTSE expression
levels were not significantly associated with survival
[hazard ratio (HR) 0.65; 95 % confidence interval (CI)
0.73–3.24, p = 0.25). CTSE expression above the 25th
percentile was associated with a non-significant 41 %
relative risk reduction for death (HR 0.59, 95 % CI
0.27–1.26, p = 0.17). In a backward stepwise regression
model including sex, age, overall tumor stage, and CTSE
expression below the 25th percentile, only age (HR 1.04,
95 % CI 1.00–1.08; p = 0.04) and AJCC stage II (HR
4.93, 95 % CI 1.88–12.88; p = 0.001) were independent
prognostic markers for decreased survival (Table 2).
DISCUSSION
This novel study shows that CTSE is highly overexpressed
in BE and BE/D compared to normal esophageal tissue. CTSE
mRNA expression was 1,000-fold higher in BE compared to
normal esophageal tissue, which we believe to be the highest
gene expression change reported for this disease. Lower levels
of CTSE mRNA were observed in EAC compared to BE. A













FIG. 2 CTSE serum values. Serum values do not differ between
pathologic patient groups, although tissue levels are markedly
increased
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normal, metaplastic, dysplastic, and neoplastic gastric epi-
thelium as well as in the intestinal dysplasia–neoplasia
sequence in APCmin/? mice.11–15 One explanation for our
observed CTSE overexpression is that exposure to gastric
refluxate induces expression of gastric proteases; consistent
with this we found that despite the remarkable induction in BE
tissues, CTSE levels are still lower than those found in either
gastric fundus or cardiac mucosa.
Alternatively, the remarkably high CTSE expression
levels may indicate a functional role in this disease.
Unfortunately, the exact function of CTSE remains to be
defined because the specific substrate for this protease is
not known.10,26 A role in host defense has been suggested
because of the high CTSE expression in immune and
antigen presenting cells, but CTSE was solely expressed in
glandular BE cells and not in stromal cells in the present
study, similar to the distribution observed in a mouse
intestinal neoplasia study.14
Interestingly, the other cathepsin family members
cathepsin B, C, K, and S are also up-regulated in BE and
EAC, and cathepsin D (CTSD) mRNA expression shows a
significant stepwise increase in erosive esophagitis, intes-
tinal metaplasia and EAC.17–20 Further functional
hypotheses for CTSE in Barrett disease involve the con-
tents of the gastro-esophageal refluxate. Intracellular and
secreted CTSD requires a low pH to exert its proteolytic
activity, leading to the speculation that CTSD activity may
be especially enhanced in the acidic environment of gas-
troesophageal reflux associated disease.20,27 CTSD is also
involved in the resistance to the bile salt deoxycholate–
induced apoptosis in colon cancer cell lines.28 Because
CTSE is highly homologous to CTSD, there may be a
similar acid and bile-associated function for CTSE in the
context of BE development.9,26
A conclusive explanation for the significantly lower
CTSE expression levels in EAC compared to BE is not
available. In particular, it is not clear if CTSE expression is
down-regulated in EAC and thus CTSE more a marker of
BE than of EAC. In other cancers, CTSE has been shown
to exert an antitumorigenic effect in prostate cancer cells—
for example, by acting as the cleavage enzyme for tumor
necrosis factor-related apoptosis ligand (TRAIL), which
has also been implicated in the pathogenesis of EAC.29,30
Injection of purified CTSE into human tumor xenografts
results in a dose-dependent induction of apoptosis and
inhibition of tumor growth.29 It can therefore be speculated
that the increased levels of CTSE in BE and BE/D may
serve a protective mechanism. In this hypothesis, the
down-regulation of CTSE marks an enhanced susceptibility
to neoplasia formation, as suggested by a mouse melanoma
study.29 Further, loss of CTSE expression has also been
shown to induce mammary gland neoplasia.31
High levels of CTSE have been shown to be associated
with improved survival in various cancers, but in EAC we
found only a non-significant trend in which expression of
CTSE above the 25th percentile resulted in a 41 % risk
reduction for death.31–33A larger study including patients
with worse disease stage could be undertaken, as limited
power and small survival differences due to the inclusion
of only early stage, chemoradiotherapy-naive patients may
have reduced our ability to detect a statistically significant
association.
Finally, although highly desirable from a clinical per-
spective, this study indicates a lack of value in measuring
CTSE protein levels in serum. Although there was a non-
significant trend to higher CTSE protein levels in patients
with EAC, our exploratory study was not powered to detect
small differences in CTSE expression between patient
groups. Alternatively, however, CTSE activity levels could
be studied according to a recent report, which showed that


























FIG. 3 CTSE mRNA expression and survival. Dichotomization at
log2-transformed 25th percentile. Patients with CTSE over the 25th
percentile show a 41 % reduction in risk for death (HR 0.59, 95 % CI
0.27–1.26; p = 0.17)
TABLE 2 Uni- and multivariable analysis for factors contributing to
mortality according to the Cox proportional hazards model
Variable Univariable analysis Multivariable analysis
HR 95 % CI p HR 95 % CI p
Age 1.04 1.00–1.08 0.04 1.04 1.00–1.08 0.04
Sex (male) 1.71 0.41–7.15 0.464 1.49 0.35–6.38 0.59
AJCC stage II 4.68 1.80–12.14 0.002 4.93 1.88–12.88 0.001
Log CTSE\25th
percentile
1.54 0.73–3.24 0.25 1.71 0.79–3.65 0.17
Log CTSE[25th
percentile
0.65 0.31–1.36 0.25 0.59 0.27–1.26 0.17
HR hazard ratio, CI 95 % confidence interval, AJCC American Joint
Committee on Cancer, CTSE cathepsin E
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with more advanced disease, recurrence, and prognosis in
patients with breast cancer.31
CONCLUSIONS
The remarkable induction of CTSE expression in BE
intestinal metaplasia and dysplasia, together with the sig-
nificant down-regulation in EAC tissues, suggests a
possible role for CTSE in the Barrett disease spectrum. The
intense CTSE protein expression in BE and lower levels of
expression in EAC could be evaluated by pathologists as a
method to simplify the evaluation of esophageal tissues,
although we acknowledge that further studies are required
to substantiate this potential benefit.
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